Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by ANIRBAN MAITRA and HAOQIANG YING.
ANIRBAN MAITRA
Connection Strength
1.026
HAOQIANG YING
  1. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2024 Nov 07.
    View in: PubMed
    Score: 0.249
  2. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2016 Feb 15; 30(4):355-85.
    View in: PubMed
    Score: 0.136
  3. Targeting a chemo-induced adaptive signaling circuit confers therapeutic vulnerabilities in pancreatic cancer. Cell Discov. 2024 Oct 29; 10(1):109.
    View in: PubMed
    Score: 0.062
  4. Molecular and Clinical Features of Pancreatic Acinar Cell Carcinoma: A Single-Institution Case Series. Cancers (Basel). 2024 Oct 09; 16(19).
    View in: PubMed
    Score: 0.062
  5. Clonal dominance defines metastatic dissemination in pancreatic cancer. Sci Adv. 2024 Mar 15; 10(11):eadd9342.
    View in: PubMed
    Score: 0.060
  6. KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T?cells. Cancer Cell. 2023 09 11; 41(9):1606-1620.e8.
    View in: PubMed
    Score: 0.057
  7. Elimination of oncogenic KRAS in genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis by CD8+ T?cells. Dev Cell. 2023 09 11; 58(17):1562-1577.e8.
    View in: PubMed
    Score: 0.057
  8. Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis. Science. 2021 Sep 17; 373(6561):eabj0486.
    View in: PubMed
    Score: 0.050
  9. PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. Nat Commun. 2021 07 30; 12(1):4626.
    View in: PubMed
    Score: 0.050
  10. Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenvironment. Cancer Discov. 2020 04; 10(4):608-625.
    View in: PubMed
    Score: 0.045
  11. Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancer. JCI Insight. 2019 07 23; 5.
    View in: PubMed
    Score: 0.043
  12. Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. Nature. 2019 04; 568(7752):410-414.
    View in: PubMed
    Score: 0.042
  13. Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. Cancer Cell. 2018 04 09; 33(4):752-769.e8.
    View in: PubMed
    Score: 0.039
  14. Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Nature. 2017 02 16; 542(7641):362-366.
    View in: PubMed
    Score: 0.036
  15. Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Nature. 2017 02 02; 542(7639):119-123.
    View in: PubMed
    Score: 0.036
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.